A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

25mg Eluxadoline

Oral Tablets

DRUG

100mg Eluxadoline

Oral Tablets

Trial Locations (6)

15236

Preferred Primary Care Physicians, Inc. /ID# 227596, Pittsburgh

30281

Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600, Stockbridge

33165

Valencia Medical & Research Center /ID# 246221, Miami

33174

Florida Research Center, Inc. /ID# 227597, Miami

73106

IPS Research Company /ID# 227594, Oklahoma City

92879

Kindred Medical Institute, LLC /ID# 227595, Corona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY